Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
44.15
-0.14 (-0.32%)
At close: May 26, 2026, 4:00 PM EDT
44.26
+0.11 (0.25%)
After-hours: May 26, 2026, 7:31 PM EDT
Sanofi Employees
Sanofi had 74,846 employees as of December 31, 2025. The number of employees decreased by 8,032 or -9.69% compared to the previous year.
Employees
74,846
Change (1Y)
-8,032
Growth (1Y)
-9.69%
Revenue / Employee
$729,489
Profits / Employee
$116,385
Market Cap
106.43B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 74,846 | -8,032 | -9.69% |
| Dec 31, 2024 | 82,878 | -3,210 | -3.73% |
| Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
| Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
| Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
| Dec 31, 2020 | 99,412 | -997 | -0.99% |
| Dec 31, 2019 | 100,409 | -3,817 | -3.66% |
| Dec 31, 2018 | 104,226 | -2,340 | -2.20% |
| Dec 31, 2017 | 106,566 | -293 | -0.27% |
| Dec 31, 2016 | 106,859 | -2,230 | -2.04% |
| Dec 31, 2015 | 109,089 | 1,702 | 1.58% |
| Dec 31, 2014 | 107,387 | -4,741 | -4.23% |
| Dec 31, 2013 | 112,128 | 154 | 0.14% |
| Dec 31, 2012 | 111,974 | -1,745 | -1.53% |
| Dec 31, 2011 | 113,719 | 12,144 | 11.96% |
| Dec 31, 2010 | 101,575 | -3,292 | -3.14% |
| Dec 31, 2009 | 104,867 | 6,654 | 6.78% |
| Dec 31, 2008 | 98,213 | -1,282 | -1.29% |
| Dec 31, 2007 | 99,495 | -794 | -0.79% |
| Dec 31, 2006 | 100,289 | 3,108 | 3.20% |
| Dec 31, 2005 | 97,181 | 742 | 0.77% |
| Dec 31, 2004 | 96,439 | 63,353 | 191.48% |
| Dec 31, 2003 | 33,086 | 650 | 2.00% |
| Dec 31, 2002 | 32,436 | 1,922 | 6.30% |
| Dec 31, 2001 | 30,514 | 1,314 | 4.50% |
| Dec 31, 2000 | 29,200 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
| Bristol-Myers Squibb Company | 32,500 |
SNY News
- 7 days ago - Sanofi: Information concerning the total number of voting rights and shares - April 2026 - GlobeNewsWire
- 7 days ago - Sanofi Reports Positive Phase 2 Data For Efdoralprin Alfa In AATD-Related Emphysema - Finanz Nachrichten
- 8 days ago - Sanofi (SNY) Presents Promising Phase 2 Study Results for Efdoralprin Alfa - GuruFocus
- 8 days ago - 1 Dirt Cheap Growth Stock to Buy Right Now - The Motley Fool
- 8 days ago - Sanofi reports ElevAATe trial of efdoralprin alfa meets primary endpoint - TheFly
- 8 days ago - Sanofi says rare lung disease drug outperforms standard care in trial - Reuters
- 8 days ago - Sanofi: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD - Finanz Nachrichten
- 8 days ago - Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD - GlobeNewsWire